Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Market watchers looked to early strength in U.S. stock index futures as investors weighed a continued pullback in AI-linked names. In company-specific trading, Taiwan Semiconductor and GE Aerospace were noted among earnings movers, while UnitedHealth drew attention as investors digested its latest results.
THE APEX TIMES
THE APEX TIMES
UnitedHealth reported better-than-expected Q2 CY2026 revenue, even as sales were flat year over year at $112 billion. The company also posted non-GAAP earnings of $6.38 per share.
THE APEX TIMES
AtaiBeckley surged about 50% ahead of the open after a market report said Eli Lilly is in talks to buy the psychedelic-focused company at a premium. Neither company confirmed the negotiations in the posting that circulated to markets.
THE APEX TIMES
Shares of the psychedelics-focused biotech AtaiBeckley surged in premarket trading after reports that Eli Lilly is in discussions about a potential deal, sending momentum into a space that has attracted both scientific and commercial interest.
THE APEX TIMES
Shares of GH Research (NASDAQ: GHRS) rose sharply in early trading after media reports said Eli Lilly (NYSE: LLY) is discussing an acquisition of psychedelic drug developer Atai Life Sciences (NASDAQ: ATAI). No companies involved confirmed the discussions in the report.
THE APEX TIMES
The largest U.S. health insurer posted results that beat market expectations for its second quarter and increased its full-year guidance, according to a report published by Yahoo Finance.
THE APEX TIMES
The Cambridge biotech said the first participant has received doses in its Phase 1 study evaluating mRNA-4200, an investigational mRNA-based treatment designed to target cancer antigens in solid tumors.
THE APEX TIMES
The acquisition gives Lilly a pipeline asset built around a DMT (dimethyltryptamine) nasal spray, which has received U.S. FDA Breakthrough Therapy Designation for treatment-resistant depression.
THE APEX TIMES
The deal, announced as a definitive agreement, would bring AtaiBeckley’s clinical-stage pipeline in treatment-resistant depression and other mental health areas into Eli Lilly’s broader research portfolio.
